Novo Nordisk

Press release

2021-12-13T06:30:53Z

2021-12-13T06:30:53Z

Download

Download pdf

Novo Nordisk invests more than DKK 17 bn in expansion of the manufacturing facilities in Kalundborg, Denmark

December 13, 2021 - Novo Nordisk today announced plans to invest more than 17 bn Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.​

The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products.​ The new facilities will be automated and include state-of-the-art production technologies.

“This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk. ​

The investment projects are expected to be finalised in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase. ​

Facts about Novo Nordisk manufacturing in Kalundborg
Novo Nordisk's production facilities in Kalundborg were established in 1969. Today, the facilities cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products. Since the turn of the millennium and until today, Novo Nordisk has invested more than 18 bn Danish kroner in the production facilities in Kalundborg. The investment announced today almost doubles 20 years of investments.

Visit novonordisk.com for photos and b-roll supporting this press release.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 4 7,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook, Twitter , LinkedIn and YouTube.

Further information

Media:   
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Michael Bachner (US)  +1 609 664 7308 mzyb@novonordisk.com 
   
Investors:   
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com 
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com 
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com 
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com 


Attachment